IDEXX Laboratories reported higher second-quarter 2026 revenue and earnings and slightly raised its full-year 2026 guidance for revenue, operating margin, and EPS. The company now expects revenue of US$4,700 million to US$4,745 million and EPS of US$14.69 to US$14.94. IDEXX also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio into the companion-animal heart disease market. The raised guidance and new test modestly support the recurring-revenue story but do not fundamentally change core drivers or risks, including pressure on U.S. vet visit volumes and pricing.
IDEXX Laboratories IncRaised 2026 guidance for revenue, operating margin, and EPS.
